C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma

导出原文传递

翻译打印收藏纠错

作者： Roccaro,A.M. ^[1] ; Sacco,A. ^[2] ; Jimenez,C. ^[3] ; Maiso,P. ^[4] ; Moschetta,M. ^[5] ; Mishima,Y. ; Aljawai,Y. ; Sahin,I. ; Kuhne,M. ; Cardarelli,P. ; Cohen,L. ; SanMiguel,J.F. ; Garcia-Sanz,R. ; Ghobrial,I.M.

作者单位： Bristol-Myers Squibb, Lawrenceville, NJ, United States ^[1] Bristol-Myers Squibb, Redwood City, CA, United States ^[2] University of Salamanca, Salamanca, Spain ^[3] Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA ^[4] University of Navarra, Pamplona, Spain ^[5]

发布时间 2014-11-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood

2014年123卷26期

4120-4131页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma

Blood

相似文献

Blood

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma

Blood

相似文献

Blood

相关期刊

检索历史清除